Unconjugated Human HLA-DRA1*01:01&HLA-DRB1*04:01&Influenza HA (PKYVKQNTLKLAT) Complex Protein (Monomer, MALS verified)

Customer Reviews
Cat. No. / Size
Price
Qty
HLA-H52E3-25ug
$120.00
HLA-H52E3-200ug
$680.00
ETA of in-stock products:2 business days

Product Details

  • Synonyms

    HLA-DRA1*0101 & HLA-DRB1*0401 & Influenza HA (PKYVKQNTLKLAT)

  • Source

    Unconjugated Human HLA-DRA1*01:01&HLA-DRB1*04:01&Influenza HA (PKYVKQNTLKLAT) Complex Protein (HLA-H52E3) is expressed from human 293 cells (HEK293). It contains AA Ile 26 - Glu 216 (HLA-DRA1*01:01) & Gly 30 - Lys 227 (HLA-DRB1*04:01) & PKYVKQNTLKLAT peptide (Accession # CAI2388006.1 (HLA-DRA1*01:01) & CAI9239961.1 (HLA-DRB1*04:01) & PKYVKQNTLKLAT).

    Predicted N-terminus: Ile 26

    Request for sequence
  • Molecular Characterization

    Unconjugated Human HLA-DRA1*01:01&HLA-DRB1*04:01&Influenza HA (PKYVKQNTLKLAT) Complex Protein is produced by co-expression of HLA-DRA1 and HLA-DRB1 loaded with Influenza HA peptide.

    This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).

    The protein has a calculated MW of 29.8 kDa and 29.0 kDa. The protein migrates as 38-41 kDa and 33-36 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Purity

    >90% as determined by SDS-PAGE.

    >95% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Customers Also Viewed

Performance Data

  • SDS-PAGE

    HLA-DRA1*0101 & HLA-DRB1*0401 & Influenza HA (PKYVKQNTLKLAT) SDS-PAGE

    Unconjugated Human HLA-DRA1*01:01&HLA-DRB1*04:01&Influenza HA (PKYVKQNTLKLAT) Complex Protein on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).

  • SEC-MALS

    HLA-DRA1*0101 & HLA-DRB1*0401 & Influenza HA (PKYVKQNTLKLAT) SEC-MALS

    The purity of Unconjugated Human HLA-DRA1*01:01&HLA-DRB1*04:01&Influenza HA (PKYVKQNTLKLAT) Complex Protein (Cat. No. HLA-H52E3) is more than 95% and the molecular weight of this protein is around 60-80 kDa verified by SEC-MALS.

    Report
  • Bioactivity-ELISA

     HLA-DRA1*0101 & HLA-DRB1*0401 & Influenza HA (PKYVKQNTLKLAT) ELISA

    Immobilized Unconjugated Human HLA-DRA1*01:01&HLA-DRB1*04:01&Influenza HA (PKYVKQNTLKLAT) Complex Protein (Cat. No. HLA-H52E3) at 1 μg/mL (100 μL/well) can bind Anti-HLA-DR Antibody, Human IgG1 with a linear range of 0.06-1 ng/mL (QC tested).

    Protocol

Customer Reviews
Writing Reviews

Background

The peptide PKYVKQNTLKLAT, derived from the hemagglutinin (HA) protein of influenza virus, is presented by the MHC class II molecule HLA-DRA1*01:01/HLA-DRB1*04:01. This complex serves as a prototypical target for virus-specific CD4⁺ T helper cells, which are crucial for generating effective antibody responses and cytotoxic T lymphocyte (CTL) memory during influenza infection and vaccination. Studying this epitope has been fundamental to understanding adaptive immunity to viral pathogens and HLA-restricted immune recognition.

Recent Advances

 
Drug Candidate Licensing
More
  • Basic Product Information
  • Product Details
  • Customers Also Viewed
  • Performance Data
  • Customer Reviews
  • Background